+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma



Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma



Journal of Neurosurgery 120(2): 331-336



The management of patients with locally recurrent or metastatic chordoma is a challenge. Preclinical disease models would greatly accelerate the development of novel therapeutic options for chordoma. The authors sought to establish and characterize a primary xenograft model for chordoma that faithfully recapitulates the molecular features of human chordoma. Chordoma tissue from a recurrent clival tumor was obtained at the time of surgery and implanted subcutaneously into NOD-SCID interleukin-2 receptor gamma (IL-2Rγ) null (NSG) mouse hosts. Successful xenografts were established and passaged in the NSG mice. The recurrent chordoma and the derived human chordoma xenograft were compared by histology, immunohistochemistry, and phospho-specific immunohistochemistry. Based on these results, mice harboring subcutaneous chordoma xenografts were treated with the mTOR inhibitor MLN0128, and tumors were subjected to phosphoproteome profiling using Luminex technology and immunohistochemistry. SF8894 is a novel chordoma xenograft established from a recurrent clival chordoma that faithfully recapitulates the histopathological, immunohistological, and phosphoproteomic features of the human tumor. The PI3K/Akt/mTOR pathway was activated, as evidenced by diffuse immunopositivity for phospho-epitopes, in the recurrent chordoma and in the established xenograft. Treatment of mice harboring chordoma xenografts with MLN0128 resulted in decreased activity of the PI3K/Akt/mTOR signaling pathway as indicated by decreased phospho-mTOR levels (p = 0.019, n = 3 tumors per group). The authors report the establishment of SF8894, a recurrent clival chordoma xenograft that mimics many of the features of the original tumor and that should be a useful preclinical model for recurrent chordoma.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053373537

Download citation: RISBibTeXText

PMID: 24286145

DOI: 10.3171/2013.10.jns13598


Related references

Establishment and characterization of a chordoma cell line from the tissue of a patient with dedifferentiated-type chordoma. Journal of Neurosurgery. Spine 25(5): 626-635, 2016

Erlotinib inhibits growth of a patient-derived chordoma xenograft. Plos one 8(11): E78895, 2013

A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology. Plos one 8(11): E79950, 2013

Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines. Journal of Neurosurgery. Spine 21(3): 386-393, 2014

Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. Annals of Oncology 28(6): 1230-1242, 2017

Three cases of intracranial chordoma. Typical chordoma and chondroid chordoma. No Shinkei Geka. Neurological Surgery 12(5): 591-598, 1984

Establishment and characterization of a primary human chordoma xenograft model. Journal of Neurosurgery 116(4): 801-809, 2012

Characterization of a Clival Chordoma Xenograft Model Reveals Tumor Genomic Instability. American Journal of Pathology 188(12): 2902-2911, 2018

Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma. Case Reports in Oncological Medicine 2018: 4290131, 2018

A comparative ultrastructural study of chondrosarcoma, chordoid sarcoma, chordoma and chordoma periphericum. Pathology Research and Practice 179(4-5): 546-559, 1985

Expression of MDR1, HIF-1α and MRP1 in sacral chordoma and chordoma cell line CM-319. Journal of Experimental and Clinical Cancer Research 29: 158, 2010

A vertebral extra dural chordoma at C5, possibly deriving from a clival chordoma. Surgical Neurology International 6: 94, 2015

Malignant chordoma of the cranial base; clivus and so-called hypophyseal chordoma. Zentralblatt für Allgemeine Pathologie U. Pathologische Anatomie 98(9-11): 512-521, 1958

Sarcomatoid chordoma: chordoma with a massive malignant spindle-cell component. Skeletal Radiology 29(12): 721-725, 2000

Chordoma cutis: a report of nineteen patients with cutaneous involvement of chordoma. Journal of the American Academy of Dermatology 29(1): 63-66, 1993